These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1127 related items for PubMed ID: 24985086

  • 1. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL.
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [Abstract] [Full Text] [Related]

  • 2. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 4. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P, Jain TK, Singh H, Suman SK, Faizi NA, Kumar R, Bal C, Malhotra A, Kumar R.
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [Abstract] [Full Text] [Related]

  • 5. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, Geatti O, Castello A, Laghai I, Popescu CE, Dolci C, Crivellaro C, Seghezzi S, Kirienko M, De Biasi V, Cocciolillo F, Quartuccio N, Young AIMN Working Group.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [Abstract] [Full Text] [Related]

  • 7. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.
    Acta Gastroenterol Belg; 2007 Mar; 70(4):331-8. PubMed ID: 18330088
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 12. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
    Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D.
    J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY, Lee CH, Seo MJ, Lee SH, Ryu JS, Lee JJ.
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X, Wu F, Han P.
    Hell J Nucl Med; 2014 Oct; 17(3):177-83. PubMed ID: 25526754
    [Abstract] [Full Text] [Related]

  • 17. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P.
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [Abstract] [Full Text] [Related]

  • 18. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y.
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET/CT for staging of penile cancer.
    Scher B, Seitz M, Reiser M, Hungerhuber E, Hahn K, Tiling R, Herzog P, Reiser M, Schneede P, Dresel S.
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.